Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
Glioblastoma (GBM) cells are often characterized by the presence of the IDH1 R132H mutation and high expression of anti-apoptotic proteins. Here, the authors show that the inhibition of Bcl-xL is synthetically lethal in IDH1-mutated GBM models and that this effect is mediated by the oncometabolite,...
Guardado en:
Autores principales: | Georg Karpel-Massler, Chiaki Tsuge Ishida, Elena Bianchetti, Yiru Zhang, Chang Shu, Takashi Tsujiuchi, Matei A. Banu, Franklin Garcia, Kevin A. Roth, Jeffrey N. Bruce, Peter Canoll, Markus D. Siegelin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0f3f4c1834e24518860d56a1a35c45d4 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems
por: Enyuan Shang, et al.
Publicado: (2018) -
Inhibition of Bcl-2/Bcl-xL and c-MET causes synthetic lethality in model systems of glioblastoma
por: Yiru Zhang, et al.
Publicado: (2018) -
Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL
por: Reut Yosef, et al.
Publicado: (2016) -
Targeting Bcl-2/Bcl-XL induces antitumor activity in uveal melanoma patient-derived xenografts.
por: Fariba Némati, et al.
Publicado: (2014) -
Development of a BCL-xL and BCL-2 dual degrader with improved anti-leukemic activity,
por: Dongwen Lv, et al.
Publicado: (2021)